NCT04385667View on ClinicalTrials.gov

LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

December 1, 2022

Study Completion Date

December 25, 2022

Conditions
Atypical Endometrial Hyperplasia
Interventions
DEVICE

levonorgestrel intrauterine system (LNG-IUD)

progestin delivery for regression of atypical endometrial hyperplasia

DRUG

Oral Megesterol 160 mg daily

progestin delivery for regression of atypical endometrial hyperplasia

Trial Locations (1)

44511

Zagazig University, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT04385667 - LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia | Biotech Hunter | Biotech Hunter